The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • Archangel@lemm.ee
    1·
    15 hours ago

    Man, when I read the terms of service, it seemed pretty clear who owned your sample…and it wasn’t me. That’s the biggest reason I have never used one of these services. It seemed like an outright scam. I can’t speak to any changes made over the years, but at the time I looked into it, it was a hard nope for me. I have no idea why anyone would voluntarily give their DNA to a company like that, without a full guarantees it wouldn’t be used exclusively for their own profit.

    • pemptago@lemmy.mlEnglish
      2·
      14 hours ago

      If you read terms of service and think anything is clear then you have a gift that not many possess. I hope you can appreciate that. Sure, there are a lot of folks who should know better, but there’s also a lot who are bad at navigating these things. It’s by design. I think it benefits us to be sympathetic and welcoming, and to direct our anger at companies and laws. We need the privacy mindset to spread and fast. I think I understand where you’re coming from though. It’s so frustrating to care about privacy more than most people.